Relmada Therapeutics
RLMD
91 hedge funds and large institutions have $40.3M invested in Relmada Therapeutics in 2023 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 26 increasing their positions, 33 reducing their positions, and 29 closing their positions.
90% more call options, than puts
Call options by funds: $307K | Put options by funds: $162K
4.49% less ownership
Funds ownership: 63.6% → 59.11% (-4.5%)
17% less funds holding
Funds holding: 110 → 91 (-19)
21% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 33
39% less capital invested
Capital invested by funds: $66.6M → $40.3M (-$26.3M)
66% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$1.87M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$1.38M |
| 3 |
PCM
Parsons Capital Management
Providence,
Rhode Island
|
+$779K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$417K |
| 5 |
GIM
Guild Investment Management
Los Angeles,
California
|
+$358K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.96M |
| 2 |
SCM
Sio Capital Management
New York
|
-$822K |
| 3 |
Walleye Capital
New York
|
-$728K |
| 4 |
HF
HRT Financial
New York
|
-$552K |
| 5 |
Morgan Stanley
New York
|
-$486K |
RLMD Hedge Fund Activity: Q1 2023 in Review
91 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q1 2023, worth a combined $40.3M — down 39% from $66.6M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of RLMD and 10 opened new positions — a net loss of 19 holders — while 33 trimmed existing stakes and 26 added.
The largest buyer was Palo Alto Investors, opening a new position worth an estimated $1.87M. The largest seller was Millennium Management, cutting an estimated $2.96M.
- 91 institutional investors held Relmada Therapeutics (RLMD) as of Q1 2023, down from 110 in Q4 2022.
- Funds reported $40.3M of Relmada Therapeutics stock for Q1 2023, down 39% quarter-over-quarter.
- 10 funds opened new Relmada Therapeutics positions in Q1 2023 and 29 closed out, a net change of -19 holders.
- The largest Relmada Therapeutics buyer in Q1 2023 was Palo Alto Investors, an estimated $1.87M added.
- The largest Relmada Therapeutics seller in Q1 2023 was Millennium Management, an estimated $2.96M sold.
Based on aggregated 13F filings for Q1 2023.